CGCG clinical practice guidelines for the management of adult diffuse gliomas.

The Chinese Glioma Cooperative Group (CGCG) Guideline Panel for adult diffuse gliomas provided recommendations for diagnostic and therapeutic procedures. The Panel covered all fields of expertise in neuro-oncology, i.e. neurosurgeons, neurologists, neuropathologists, neuroradiologists, radiation and medical oncologists and clinical trial experts. The task made clearer and more transparent choices about outcomes considered most relevant through searching the references considered most relevant and evaluating their value. The scientific evidence of papers collected from the literature was evaluated and graded based on the Oxford Centre for Evidence-based Medicine Levels of Evidence and recommendations were given accordingly. The recommendations will provide a framework and assurance for the strategy of diagnostic and therapeutic measures to reduce complications from unnecessary treatment and cost. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China.

Yu Wang | Lei Han | Pei Yang | Wei Yan | Shaowu Li | Ying Mao | Yuan Yang | Jing Chen | Qing Mao | Hongmin Bai | Tao Jiang | Yu Yao | Jun Dong | Zhixiong Lin | Chuanbao Zhang | Zheng Wang | Xiaoguang Qiu | Chunsheng Kang | Xing Liu | Ke Sai | Xinting Wei | Zhaoshi Bao | Zheng Wang | Y. Mao | T. Jiang | Chuanlu Jiang | Xuejun Li | C. Kang | Y. You | Yan-wei Liu | Huimin Hu | Hongmin Bai | Weimin Wang | Q. Mao | K. Sai | J. Chen | Xing Fan | Yu Yao | Yu Wang | Wenbin Ma | Xing Liu | Shaowu Li | Shuai Liu | Yongzhi Wang | Chuanbao Zhang | Baoshi Chen | Wenbin Li | Z. Bao | Wei Yan | Wei Zhang | K. Yao | X. Qiu | Xuejun Yang | Xiaodong Ma | Xing Fan | Yuan Yang | Yanwei Liu | Huimin Hu | Yinyan Wang | Kun Yao | Wei Zhang | Qixue Wang | Anhua Wu | Gan You | Yongzhi Wang | Chuanlu Jiang | Yongping You | Zhixiong Liu | Yu-Qing Liu | S. Lv | Jun Dong | Ling Chen | Wenbin Ma | Jinquan Cai | Zhixiong Liu | A. Wu | Shuai Liu | Xuejun Yang | Xuejun Li | Ling Chen | Weimin Wang | Wenbin Li | Shouwei Li | Guilin Li | Baoshi Chen | Xianzhi Liu | Zhiwen Zhang | Yiwu Dai | Shengqing Lv | Liang Wang | Guozheng Xu | Xiaodong Ma | Hongjun Wang | Lingchao Chen | Yuqing Liu | Zhiliang Wang | Guozheng Xu | Guilin Li | Jinquan Cai | Lei Han | G. You | Shouwei Li | Qi-xue Wang | Pei Yang | Xinting Wei | Zhiwen Zhang | Hongjun Wang | Zhixiong Lin | Zheng Wang | Liang Wang | Yiwu Dai | Yin-yan Wang | Lingchao Chen | Zhiliang Wang | Xianzhi Liu | Chuan-bao Zhang | Qixue Wang | Xiaoguang Qiu | Yanwei Liu

[1]  T. Jiang,et al.  Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma , 2016, Oncoimmunology.

[2]  T. Jiang,et al.  Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. , 2012, Neuro-oncology.

[3]  T. Jiang,et al.  Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors , 2015, Oncotarget.

[4]  T. Jiang,et al.  Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma. , 2011, Chinese medical journal.

[5]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Susan M. Chang,et al.  Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[8]  E. Shaw,et al.  Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. , 2008, Journal of neurosurgery.

[9]  D. Brachman,et al.  Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study , 2017, The Lancet.

[10]  T. Tominaga,et al.  Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion , 2016, Journal of Neuro-Oncology.

[11]  G. Reifenberger,et al.  Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  E. Shaw,et al.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. , 2006, Cancer research.

[13]  Susan M. Chang,et al.  Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). , 2010, Neuro-oncology.

[14]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[15]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[16]  S. Li,et al.  Anatomic Location of Tumor Predicts the Accuracy of Motor Function Localization in Diffuse Lower-Grade Gliomas Involving the Hand Knob Area , 2017, American Journal of Neuroradiology.

[17]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[18]  Caterina Giannini,et al.  Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Sommer,et al.  Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Reifenberger,et al.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Pieter Wesseling,et al.  International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading , 2014, Brain pathology.

[23]  M. J. van den Bent,et al.  The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis , 2017, Neuro-oncology.

[24]  M. Nikiforova,et al.  Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. , 2014, Neuro-oncology.

[25]  Zhifeng Shi,et al.  TERT promoter mutations contribute to subset prognostication of lower-grade gliomas , 2015, Modern Pathology.

[26]  Ying Zheng,et al.  Transition over 35 years in the incidence rates of primary central nervous system tumors in Shanghai, China and histological subtyping based on a single center experience spanning 60 years. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[27]  T. Jiang,et al.  Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution , 2013, Journal of Neuro-Oncology.

[28]  Dario J. Englot,et al.  Extent of Surgical Resection Predicts Seizure Freedom in Low-Grade Temporal Lobe Brain Tumors , 2012, Neurosurgery.

[29]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[30]  J. Perry Thromboembolic disease in patients with high-grade glioma. , 2012, Neuro-oncology.

[31]  Y. Marie,et al.  Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes , 2014, Neurology.

[32]  R Grant,et al.  Guidelines on management of low‐grade gliomas: report of an EFNS–EANO * Task Force , 2010, European journal of neurology.

[33]  J. Doudna,et al.  Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma , 2011 .

[34]  Timothy C. Ryken,et al.  Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery , 2008, Journal of Neuro-Oncology.

[35]  David T. W. Jones,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[36]  M. Chamberlain Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study , 2015, Journal of Neuro-Oncology.

[37]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[38]  Michael Platten,et al.  Treatment of anaplastic glioma. , 2015, Cancer treatment and research.

[39]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[40]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[41]  F. Jolesz,et al.  Survival rates in patients with low‐grade glioma after intraoperative magnetic resonance image guidance , 2005, Cancer.

[42]  B. Fisher,et al.  Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Winand N M Dinjens,et al.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  S. Coons,et al.  Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. , 2015, International journal of radiation oncology, biology, physics.

[45]  Martin Sill,et al.  Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. , 2014, Neuro-oncology.

[46]  J. Tonn,et al.  Molecular imaging of gliomas with PET: opportunities and limitations. , 2011, Neuro-oncology.

[47]  R. McLendon,et al.  Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. , 2011, Neuro-oncology.

[48]  Lei Wang,et al.  Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China , 2012, PloS one.

[49]  C. Finch,et al.  A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures , 2010, Journal of Neuro-Oncology.

[50]  R. McLendon,et al.  Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas , 2012, Oncotarget.

[51]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[52]  Satoshi O. Suzuki,et al.  Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and 18F-fluorodeoxyglucose positron emission tomography , 2013, Neuroradiology.

[53]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[54]  Cynthia Ménard,et al.  Advances in Magnetic Resonance Imaging and Positron Emission Tomography Imaging for Grading and Molecular Characterization of Glioma. , 2015, Seminars in radiation oncology.

[55]  In-Hee Lee,et al.  Spatiotemporal Evolution of the Primary Glioblastoma Genome. , 2015, Cancer cell.

[56]  E. Shaw,et al.  Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. , 2014 .

[57]  H. Iseki,et al.  Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI. , 2017, Journal of neurosurgery.

[58]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[59]  Michael A. Choti,et al.  DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.

[60]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[61]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[62]  Roland Eils,et al.  Recurrent MET fusion genes represent a drug target in pediatric glioblastoma , 2016, Nature Medicine.

[63]  M. Mehta,et al.  A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913 , 2018, Neuro-oncology.

[64]  P. Varlet,et al.  Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours , 2017, Acta Neuropathologica Communications.

[65]  M. Nykter,et al.  The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. , 2013, The Journal of clinical investigation.

[66]  M. Chan Recent Technical Advances and Indications for Radiation Therapy in Low-Grade Glioma. , 2015, Seminars in radiation oncology.

[67]  E. Shaw,et al.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Steven J. M. Jones,et al.  Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.

[69]  David T. W. Jones,et al.  ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma , 2014, Acta Neuropathologica.

[70]  P. Kleihues,et al.  TERT promoter mutations in primary and secondary glioblastomas , 2013, Acta Neuropathologica.

[71]  Ashley R. Woodfin,et al.  Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas , 2017, Nature Medicine.

[72]  Satoru Miyano,et al.  Mutational landscape and clonal architecture in grade II and III gliomas , 2015, Nature Genetics.

[73]  E. Chiocca,et al.  Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. , 2015, Neuro-oncology.

[74]  B. Rosen,et al.  Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma , 2017, Journal of Neuro-Oncology.

[75]  Susan M. Chang,et al.  Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? , 2011, Neuro-oncology.

[76]  B. Nahed,et al.  Low-grade gliomas. , 2014, The oncologist.

[77]  Naoya Hashimoto,et al.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.

[78]  Denis Lacombe,et al.  Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  M. J. van den Bent,et al.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  J. Mcsherry Spice, pot, and stroke , 2014, Neurology.

[81]  E. Shaw,et al.  Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  M. Taphoorn,et al.  Efficacy of anti-epileptic drugs in patients with gliomas and seizures , 2009, Journal of Neurology.

[83]  Chao You,et al.  Statistical Report of Central Nervous System Tumors Histologically Diagnosed in the Sichuan Province of China from 2008 to 2013: A West China Glioma Center Report , 2016, Annals of Surgical Oncology.

[84]  Jennie W. Taylor,et al.  Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT , 2017, Acta Neuropathologica.

[85]  H. Duffau Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up , 2015, Acta Neurochirurgica.

[86]  T. Jiang,et al.  IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry , 2015, Oncotarget.

[87]  Luciano Fadiga,et al.  Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients: clinical article. , 2012, Journal of neurosurgery.

[88]  A. Vortmeyer,et al.  Integrated genomic characterization of IDH1-mutant glioma malignant progression , 2015, Nature Genetics.

[89]  D. Orringer,et al.  Advances in the Surgical Management of Low-Grade Glioma. , 2015, Seminars in radiation oncology.

[90]  N. Laperriere,et al.  Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[91]  S. Taillibert,et al.  Anaplastic glioma: current treatment and management , 2015, Expert review of neurotherapeutics.

[92]  G. Reifenberger,et al.  EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. , 2013, Cancer cell.

[93]  A. Verma MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[94]  P. Lanteri,et al.  Surgical treatment of high-grade gliomas in motor areas. The impact of different supportive technologies: a 171-patient series , 2010, Journal of Neuro-Oncology.

[95]  Mitchel S Berger,et al.  Seizure characteristics and control following resection in 332 patients with low-grade gliomas. , 2008, Journal of neurosurgery.

[96]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[97]  L. C. Hinske,et al.  In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing , 2013, Acta Neuropathologica.

[98]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[99]  L. Recht,et al.  Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors , 2000, Neurology.

[100]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[101]  R. Stupp,et al.  New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. , 2012, European journal of cancer.

[102]  L. Deangelis,et al.  Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  G. Reifenberger,et al.  European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. , 2017, The Lancet. Oncology.

[104]  Act Investigators Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial , 2017 .

[105]  T. Holland-Letz,et al.  ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis , 2013, Acta Neuropathologica.

[106]  Xiuli Wang,et al.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.

[107]  Henry Brem,et al.  Independent association of extent of resection with survival in patients with malignant brain astrocytoma. , 2009, Journal of neurosurgery.

[108]  C. Vecht,et al.  Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids. , 2016, Neuro-oncology practice.

[109]  B. Porse,et al.  EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas , 2017, Nature Medicine.

[110]  L Junck,et al.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. , 2011, The Lancet. Oncology.

[111]  M. Berger,et al.  Differentiation of Glioblastoma Multiforme and Single Brain Metastasis by Peak Height and Percentage of Signal Intensity Recovery Derived from Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging , 2007, American Journal of Neuroradiology.

[112]  E. Bruera,et al.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[114]  Y. Marie,et al.  Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes , 2014, Neurology.

[115]  Mitchel S Berger,et al.  An extent of resection threshold for newly diagnosed glioblastomas. , 2011, Journal of neurosurgery.

[116]  A. Iavarone,et al.  Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma , 2015, Clinical Cancer Research.

[117]  Guido Reifenberger,et al.  Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma‐Tailored Gene Panel , 2017, Brain pathology.

[118]  K. Hoang-Xuan,et al.  MGMT methylation: A marker of response to temozolomide in low‐grade gliomas , 2006, Annals of neurology.

[119]  J. Buckner,et al.  The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma , 2017, Journal of Neuro-Oncology.

[120]  T. Jiang,et al.  Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China , 2013, Journal of Cancer Research and Clinical Oncology.

[121]  G. Reifenberger,et al.  Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation , 2013, Neurology.

[122]  N. Pouratian,et al.  Surgery Insight: the role of surgery in the management of low-grade gliomas , 2007, Nature Clinical Practice Neurology.

[123]  Paul S Mischel,et al.  Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  S. Frisch,et al.  Post-Surgical Language Reorganization Occurs in Tumors of the Dominant and Non-Dominant Hemisphere , 2017, Clinical Neuroradiology.

[125]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[126]  R. Stupp,et al.  Epilepsy in brain tumor patients. , 2010, Current opinion in neurology.

[127]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[128]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[129]  D. Osoba,et al.  Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma , 2017, The New England journal of medicine.

[130]  J. Akers,et al.  RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas , 2014, Genome research.

[131]  R. Stupp,et al.  Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082) , 2016, Clinical Cancer Research.

[132]  M Brada,et al.  High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[133]  W. Dinjens,et al.  Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification , 2017, Acta Neuropathologica.

[134]  Y. Marie,et al.  O6.08COMBINED ANALYSIS OF TERT, EGFR AND IDH STATUS DEFINE DISTINCT PROGNOSTIC CLASSES OF GLIOBLASTOMA , 2014 .

[135]  T. Jiang,et al.  Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas , 2015, PloS one.

[136]  Didier Frappaz,et al.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[137]  G. Reifenberger,et al.  EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.

[138]  H Duffau,et al.  Temozolomide for low-grade gliomas , 2007, Neurology.

[139]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[140]  D. Brat,et al.  Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.

[141]  David J. Yang,et al.  Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.

[142]  M. Weller,et al.  Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide , 2010, Journal of Neuro-Oncology.

[143]  Alexander R. Pico,et al.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.

[144]  G. Reifenberger,et al.  Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. , 2015, Neuro-oncology.

[145]  Chul-Kee Park,et al.  The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas , 2017, Acta Neuropathologica Communications.

[146]  Zhifeng Shi,et al.  Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors , 2014, Modern Pathology.

[147]  R. McLendon,et al.  Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.

[148]  R. Stupp,et al.  Epilepsy meets cancer: when, why, and what to do about it? , 2012, The Lancet. Oncology.

[149]  Frank M. Sacks,et al.  IDH 1 and IDH 2 Mutations in Gliomas , 2009 .

[150]  V. Tabar,et al.  The Role of Extent of Resection in IDH1 Wild‐Type or Mutant Low‐Grade Gliomas , 2018, Neurosurgery.

[151]  T. Jiang,et al.  Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. , 2016, Neuro-oncology.

[152]  G. Reifenberger,et al.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  G. Spena,et al.  Supratentorial Gliomas in Eloquent Areas: Which Parameters Can Predict Functional Outcome and Extent of Resection? , 2013, PloS one.

[154]  M. Rosenblum,et al.  Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true “oligoastrocytoma”? , 2014, Acta Neuropathologica.

[155]  Raul Rabadan,et al.  The integrated landscape of driver genomic alterations in glioblastoma , 2013, Nature Genetics.

[156]  Luc Taillandier,et al.  Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.

[157]  In-Hee Lee,et al.  Clonal evolution of glioblastoma under therapy , 2016, Nature Genetics.

[158]  H. Donovan,et al.  I could lose everything: understanding the cost of a brain tumor , 2007, Journal of Neuro-Oncology.

[159]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[160]  K. Hoang-Xuan,et al.  TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations , 2014, British Journal of Cancer.

[161]  G. Reifenberger,et al.  MGMT testing—the challenges for biomarker-based glioma treatment , 2014, Nature Reviews Neurology.

[162]  Martin Sill,et al.  Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma , 2014, Acta Neuropathologica.

[163]  K. Hopkins,et al.  Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  D. Brachman,et al.  A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: Preliminary results of RTOG 0424. , 2013 .

[165]  Cancer Care Ontario Practice Guidelines Initiative , 2003 .

[166]  Geirmund Unsgård,et al.  Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. , 2012, JAMA.

[167]  Tao Jiang,et al.  Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study. , 2011, Chinese medical journal.

[168]  E. Galanis,et al.  Medical management of high-grade astrocytoma: current and emerging therapies. , 2014, Seminars in oncology.

[169]  K. Hoang-Xuan,et al.  All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 , 2010, Neurology.

[170]  B. Scheithauer,et al.  Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[171]  K. Hoadley,et al.  miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. , 2012, Neuro-oncology.

[172]  Hugues Duffau,et al.  Surgery of low-grade gliomas: towards a ‘functional neurooncology’ , 2009, Current opinion in oncology.

[173]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[174]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[175]  J. Uhm Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .

[176]  Gabriele Schackert,et al.  Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups , 2015, Acta Neuropathologica.

[177]  Albert Lai,et al.  Time course of imaging changes of GBM during extended bevacizumab treatment , 2008, Journal of Neuro-Oncology.

[178]  G. Reifenberger,et al.  Molecular neuro-oncology in clinical practice: a new horizon. , 2013, The Lancet. Oncology.

[179]  Ludomir Stefańczyk,et al.  Cortical mapping by functional magnetic resonance imaging in patients with brain tumors , 2005, European Radiology.

[180]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[181]  T. Jiang,et al.  ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples , 2014, Oncotarget.

[182]  P. Cochat,et al.  Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[183]  A. Karim,et al.  Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  M. Weller,et al.  European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. , 2017, The Lancet. Oncology.

[185]  K. Hoang-Xuan,et al.  Chromosome 1p loss: A favorable prognostic factor in low‐grade gliomas , 2005, Annals of neurology.

[186]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[187]  F. Lieberman,et al.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.

[188]  David T. W. Jones,et al.  Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma , 2014, Acta Neuropathologica.

[189]  Ying Mao,et al.  TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas , 2015, Oncotarget.

[190]  Raymond Sawaya,et al.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[191]  Susan M. Chang,et al.  Response Assessment in Neuro-Oncology Clinical Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[192]  H. Duffau,et al.  Supratotal resection of diffuse gliomas - an overview of its multifaceted implications. , 2017, Neuro-Chirurgie.

[193]  H. Iseki,et al.  Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype. , 2013, Neurologia medico-chirurgica.

[194]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.